Original article
Hepatic amyloidosis (Primary [AL], immunoglobulin light chain): The natural history in 80 patients

https://doi.org/10.1016/0002-9343(88)90505-0Get rights and content

Abstract

Purpose: We wished to study patients with a premortem diagnosis of primary hepatic amyloidosis to determine what clinical and laboratory features might assist in recognizing the disease and assessing prognosis.

Patients and methods: A group of 80 patients with liver biopsy proven primary hepatic amyloidosis was followed from diagnosis to death.

Results: At presentation, 77 percent of the group had an associated nephrotic syndrome, congestive heart failure, peripheral neuropathy, or orthostatic hypotension. Certain clues suggested the diagnosis of hepatic amyloidosis in patients with liver disease, including the following: (1) proteinuria (88 percent); (2) abnormal serum protein electrophoresis (monoclonal protein or hypogammaglobulinemia, 64 percent); (3) hyposplenism on the peripheral blood smear (62 percent), defined by the presence of Howell-Jolly bodies; and (4) hepatomegaly disproportional to the liver enzyme abnormalities. Liver function tests were not sensitive or specific. Hepatomegaly from amyloid was frequently seen, with normal levels of alkaline phosphatase, aspartate aminotransferase, and bilirubin (32 percent). Myeloma was diagnosed in 11 patients but had no effect on the clinical course. In vitro coagulation abnormalities were common, bleeding was infrequent, and liver biopsy carried a slightly increased risk. The median survival of the entire group was nine months, and projected five- and 10-year survival rates were 13 and 1 percent, respectively.

Conclusion: Because survival is poor and no clinical features permit prospective recognition of those patients in whom the disease is likely to have an indolent course, a trial of therapy is warranted in all patients.

References (55)

  • RE Randall et al.

    Manifestations of systemic light chain deposition

    Am J Med

    (1976)
  • HS Bowman

    Acquired fibrinogenopenia

    Am J Med

    (1958)
  • MA Gertz et al.

    Response of primary hepatic amyloidosis to melphalan and prednisone: a case report and review of the literature

    Mayo Clin Proc

    (1986)
  • RA Kyle et al.

    Primary amyloidosis and acute leukemia associated with melphalan therapy

    Blood

    (1974)
  • PR Greipp

    Amyloidosis (AL)

  • SH Salzman et al.

    The differential diagnosis of giant liver

  • MP Skander et al.

    Severe intrahepatic cholestasis and rapidly progressive renal failure in a patient with immunocyte-related amyloidosis

    J Clin Gastroenterol

    (1987)
  • DM Spain et al.

    Jaundice in amyloidosis of the liver

    Am J Clin Pathol

    (1944)
  • DC Dahlin

    Amyloidosis

  • M Levy et al.

    The liver in amyloidosis

    Digestion

    (1974)
  • RA Kyle

    Amyloidosis

  • OJ Kozicky et al.

    Splenic amyloidosis: a case report of spontaneous splenic rupture with a review of the pertinent literature

    Am J Gastroenterol

    (1987)
  • RL Lipson et al.

    The postsplenectomy blood picture

    Am J Clin Pathol

    (1959)
  • KJ Isselbacher et al.

    Infiltrative and metabolic diseases affecting the liver

  • JK Camoriano et al.

    Acquired factor X deficiency and amyloidosis treated with melphalan and prednisone

    N Engl J Med

    (1987)
  • PA Galbraith et al.

    Acquired factor X deficiency: altered plasma antithrombin activity and association with amyloidosis

    JAMA

    (1974)
  • S Itescu

    Hepatic amyloidosis: an unusual cause of ascites and portal hypertension

    Arch Intern Med

    (1984)
  • Cited by (0)

    This investigation was supported in part by the Quade Amyloid Research Fund

    View full text